8-K: Confluent Supplements Merger Proxy Amid Shareholder Lawsuits

Confluent, Inc. has filed supplemental disclosures to its proxy statement for the IBM merger following multiple shareholder demand letters and lawsuits alleging misleading information.

Summary

• Confluent, Inc. (CFLT) entered into an Agreement and Plan of Merger with International Business Machines Corporation (IBM) on December 7, 2025, which will result in Confluent becoming a wholly-owned subsidiary of IBM.
• A definitive proxy statement was filed on January 9, 2026, and mailed to stockholders for a special meeting scheduled for February 12, 2026, at 9:00 a.m. Pacific time, where stockholders will vote on the merger.
• Confluent has received 17 demand letters from purported stockholders alleging misrepresentations or omissions in the proxy statement, violating federal securities laws.
• Two lawsuits were filed in the Supreme Court of the State of New York, County of New York: Stewart v. Confluent, Inc., et al. on January 21, 2026, and Kent v. Confluent, Inc., et al. on January 22, 2026, both asserting New York common law claims for negligent misrepresentation and concealment.
• Confluent denies the allegations and believes its original disclosures comply with applicable law, but voluntarily issued supplemental disclosures to moot the claims and minimize litigation risks without admitting liability or wrongdoing.
• The supplemental disclosures amend sections of the proxy statement related to Morgan Stanley's financial analysis, including details on outstanding shares, options, RSUs, estimated future net cash, valuation multiples, and discount rates.
• Key inputs for Morgan Stanley's analysis as of December 5, 2025, included 353.2 million outstanding shares, 17.2 million shares underlying options (weighted-average exercise price of $8.35), and 19.3 million shares underlying RSUs.
• Morgan Stanley's discounted equity value analysis used an estimated future net cash of approximately $1.5 billion and applied forward multiples of aggregate value to revenue of 5.0x to 8.0x to Confluent's estimated 2028 revenue.
• For discounted cash flow analysis, Morgan Stanley used Confluent's net cash of approximately $890 million as of September 30, 2025, and a discount rate ranging from 11.1% to 12.8%.
• Equity research analysts' price targets as of December 5, 2025, ranged from $24.00 to $36.00 per share, with a median of $28.00 per share.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly-positive development. While the lawsuits are a negative, the company's proactive (though denied as necessary) supplemental disclosures aim to clear the path for the IBM merger, which is a significant strategic event.

Positives

• Confluent is proceeding with the merger with IBM, indicating a strategic acquisition that could offer long-term benefits.
• Management is proactively addressing shareholder concerns by providing supplemental disclosures, aiming to mitigate litigation risks and facilitate the merger process, despite denying any legal necessity or materiality of such disclosures.

Negatives

• The company faces 17 demand letters and two active lawsuits from purported stockholders alleging material misrepresentations and omissions in the merger proxy statement.
• The necessity of issuing supplemental disclosures, even if voluntary and without admission of wrongdoing, suggests potential perceived deficiencies in the original proxy statement that could create uncertainty.

Risks

• The timing, receipt, and terms of any required governmental and regulatory approvals for the proposed transaction could delay or cause the abandonment of the merger.
• There is a risk that Confluent's stockholders may not approve the proposed transaction at the special meeting.
• The parties to the Merger Agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• The proposed transaction could disrupt management time from ongoing business operations.
• Announcements relating to the proposed transaction could have adverse effects on the market price of Confluent's common stock.
• There is a risk of unexpected costs or expenses resulting from the proposed transaction.
• Ongoing and potential future litigation relating to the proposed transaction could incur significant costs and divert resources.
• The proposed transaction and its announcement could adversely affect Confluent's ability to retain and hire key personnel and maintain relationships with customers, vendors, partners, employees, and other stakeholders, impacting operating results and business generally.

Future Outlook

The filing primarily focuses on past events and current actions related to the ongoing merger with IBM. It reiterates the expectation of the special meeting on February 12, 2026, for stockholders to vote on the merger. Forward-looking statements are general disclaimers regarding the benefits and timeline for closing the proposed transaction and potential risks associated with it.

Management Comments

• Confluent believes that the disclosures set forth in the proxy statement comply fully with applicable law and denies the allegations in the pending Complaints and Demand Letters and believes no further disclosure is required to supplement the proxy statement under applicable laws.
• However, solely to moot the claims in the Demand Letters and Complaints and minimize the risk, costs, burden, nuisance and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, Confluent has determined to voluntarily supplement the disclosures contained in the proxy statement with the disclosures set forth herein.
• The Company vigorously denies all allegations in the Demand Letters and the Complaints, including that any additional disclosure was or is required, and believes that the supplemental disclosures contained herein are immaterial.

Industry Context

StockSavvy.ai notes that shareholder lawsuits challenging merger proxy statements are a common occurrence in M&A transactions, often seeking additional disclosures. The voluntary supplemental disclosures, while denying wrongdoing, are a typical strategy to mitigate litigation risk and avoid potential delays or complications in the merger process. The acquisition of Confluent by IBM aligns with a broader trend of larger tech companies acquiring specialized cloud and data infrastructure providers to enhance their enterprise offerings.

Comparison to Industry Standards

• The selected precedent transactions used by Morgan Stanley for valuation (e.g., Anaplan/Thoma Bravo, Medallia/Thoma Bravo, HashiCorp/IBM, Splunk/Cisco) provide a benchmark for M&A multiples in the software and cloud services sector. These transactions show a range of Aggregate Value / NTM Revenue multiples from 3.4x (Semrush Holdings, Inc. / Adobe Inc.) to 12.9x (Anaplan, Inc. / Thoma Bravo, LP).
• Confluent's estimated future net cash of $1.5 billion and net cash of $890 million as of September 30, 2025, indicate a healthy cash position, which is generally favorable compared to companies with high debt burdens in similar M&A scenarios.
• The discount rates (12.7% cost of equity, 11.1% to 12.8% WACC) used by Morgan Stanley are within typical ranges for technology companies, reflecting market risk and capital structure.

Legal Proceedings

• 17 demand letters received from purported Confluent stockholders alleging misrepresentations/omissions in the proxy statement.
• Stewart v. Confluent, Inc., et al., Index No. 650388/2026, filed on January 21, 2026, in the Supreme Court of the State of New York, County of New York, alleging negligent misrepresentation and concealment.
• Kent v. Confluent, Inc., et al., Index No. 650414/2026, filed on January 22, 2026, in the Supreme Court of the State of New York, County of New York, alleging negligent misrepresentation and concealment.
• Additional lawsuits may be filed, and additional demand letters may be received before the special meeting or consummation of the merger.

Stakeholder Impact

• Shareholders will vote on the merger on February 12, 2026. The supplemental disclosures aim to provide more complete information for their voting decision and address concerns raised by other shareholders. The merger, if approved, will result in Confluent becoming a wholly-owned subsidiary of IBM, impacting their ownership structure.
• Management and employees face potential disruption of management time due to the proposed transaction and a risk of adverse effects on the ability to retain and hire key personnel.
• Customers, vendors, and partners face a risk of adverse effects on maintaining relationships due to the proposed transaction and its announcement.

Next Steps

• Special meeting of Confluent stockholders on February 12, 2026, to consider and vote on the consummation of the Merger.
• Potential for additional lawsuits or demand letters before the special meeting or consummation of the merger.
• Consummation of the Merger, subject to stockholder approval and other conditions.

Key Dates

Recommendation

The filing primarily addresses procedural and legal aspects of an ongoing merger. While the lawsuits introduce some uncertainty, the company's proactive supplemental disclosures aim to mitigate these risks and keep the merger on track. Investors currently holding Confluent shares should likely hold, awaiting the outcome of the shareholder vote and merger completion, as the core strategic event (acquisition by IBM) remains in play. New investors might find the current situation too uncertain for a strong buy, but the underlying merger agreement provides a floor.

Keywords

Confluent, IBM, Merger, Acquisition, Proxy Statement, SEC Filing, 8-K, Shareholder Lawsuit, Litigation, Corporate Governance, Financial Analysis, CFLT, Data Streaming, Cloud Software